EWTX Edgewise Therapeutics, Inc.
Edgewise Therapeutics, Inc. (EWTX) is expected to report earnings on November 5, 2026, before the market open. The consensus earnings estimate is a loss of $0.55 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +0.1% since its last earnings release on August 6, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Edgewise Therapeutics, Inc.
Edgewise Therapeutics Inc. is a clinical-stage biopharmaceutical company. It is focused on developing orally bioavailable, small molecule therapies for rare muscle disorders. Edgewise Therapeutics Inc. is based in Boulder, United States.
Sector
Healthcare
Industry
Biotechnology